Intellia borrows up to $400m against a gene editing launch

Intellia Therapeutics announced a senior secured term loan from OrbiMed on 4 September 2026 for up to $400m. Seventy-five million dollars was funded at closing. A further $225m sits behind five milestone-gated tranches tied to lonvo-z, and $100m more is available during the five-year term only if both parties agree to it.

Lonvoguran ziclumeran, or lonvo-z, is an in vivo CRISPR therapy for hereditary angioedema, a condition that produces unpredictable swelling attacks which can close an airway and which patients otherwise manage with lifelong prophylaxis. Intellia is carrying it toward US approval and commercial launch. The second named programme, nexiguran ziclumeran, is in clinical development for transthyretin amyloidosis.

The structure is the interesting part. This is debt rather than equity, so it funds a commercial launch without issuing shares — which a company at this stage would otherwise do at whatever price the market happened to offer that week. Editing a gene inside a living person has become, for this company, close enough to a sellable product that a lender will underwrite it against milestones.

None of that is a clinical result. It is a financing, and the milestones the later tranches depend on have not been reached yet.